Comment on

• Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

  Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM. Harker WG, et al. J Clin Oncol. 1985 Nov;3(11):1463-70. doi: 10.1200/JCO.1985.3.11.1463. J Clin Oncol. 1985. PMID: 4056840
• Systemic chemotherapy for advanced bladder cancer: update and controversies.

  Garcia JA, Dreicer R. Garcia JA, et al. J Clin Oncol. 2006 Dec 10;24(35):5545-51. doi: 10.1200/JCO.2006.08.0564. J Clin Oncol. 2006. PMID: 17158540 Review.
• Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.

  Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC; National Cancer Institute. Hussain MH, et al. J Clin Oncol. 2007 Jun 1;25(16):2218-24. doi: 10.1200/JCO.2006.08.0994. J Clin Oncol. 2007. PMID: 17538166 Clinical Trial.
• Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

  Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ, Sweeney CJ; Hoosier Oncology Group. Hahn NM, et al. J Clin Oncol. 2011 Apr 20;29(12):1525-30. doi: 10.1200/JCO.2010.31.6067. Epub 2011 Mar 21. J Clin Oncol. 2011. PMID: 21422406 Clinical Trial.